Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12
Authors: Crump Michael , Kuruvilla John , Couban Stephen , Macdonald David , Kukreti Vishal , Kouroukis C. Tom , Meyer Ralph M. , Rubinger Morel , Buckstein Rena , Imrie Kevin R , Federico Massimo , Renzo Nicola Di , Howson-Jan Kang , Baetz Tara , Kaizer Leonard , Voralia Michael , Olney Harold J. , Turner A. Robert , Sussman Jonathan , Hay Annette E , Djurfeldt Marina , Chen Bingshu E , Shepherd Lois 
Published: October 2019

Abstract
Abstract 745

Background:
The optimum chemotherapy combination prior to autologous stem cell transplantation (ASCT) for patients with relapsed or refractory aggressive non-Hodgkin lymphomas (NHL) has not been defined. We previously established the safety and efficacy of outpatient treatment with GDP in a phase II study (Crump et al, Cancer 2004) leading to this phase III trial testing the hypothesis that GDP is as effective and less toxic than standard DHAP, and potentially associated with better quality of life (QoL) and less resource utilization.

Methods:
Patients (pts) with relapsed/refractory aggressive NHL were stratified by IPI score at relapse (0, 1 vs 2,vs >=3 risk factors), immunophenotype (B vs T cell), disease status following initial treatment (response duration < 1yr vs duration > 1yr vs no response/PD) and prior treatment with rituximab (R); and were randomized to 2–3 21-day cycles of G 1000 mg/m2 day 1 & 8, D 40 mg day 1–4, P 75 mg/m2day 1 or standard DHAP. Pts with CR, PR (or SD, per institutional policy) proceeded to PBSC collection and ASCT. The protocol was amended 11/2005 to include R with GDP or DHAP for pts with CD20+ lymphoma. Co-primary endpoints were response rate (RR) after 2 cycles (CR/CRu/PR) according to 1999 International Workshop criteria, and transplantation rate; FDG-PET was not used to determine response. Using a non-inferiority design, the study was powered to exclude a 10% difference in RR between GDP and DHAP (α 0.05, power 80%). Other endpoints included toxicity, event-free (EFS) and overall survival (OS), QoL and an economic analysis. FACT-G, FACT-CNS and FACT-LYM instruments and validated lymphoma-specific questions were used to assess QoL. Results of a second randomization to post-ASCT rituximab consolidation vs observation for pts with CD20+ lymphoma will be reported subsequently.

Results:
From 8/2003 to 11/2011, 619 pts were enrolled at 52 centres in Canada, Italy, Australia and the US (GDP 310 DHAP 309). Pt characteristics: median age 55 yrs (28.4% >60 y); histology: DLBCL 71%, PTCL 4%, ALCL 4%, transformed 14%; IPI risk factors: 0,1: 38%, 2: 29%; >3: 33%; elevated LDH 59%; prior R treatment 67%; refractory to initial therapy 31%; all baseline characteristics were balanced between treatment arms. In the intention to treat (ITT) population, RR for GDP was 45.2% and for DHAP 44.0%. The upper boundary of the one-sided 95.6% confidence interval for the difference in RRs was 5.67% and did not cross the pre-specified 10% non-inferiority boundary, meaning protocol-stated criteria for declaring GDP non-inferior to DHAP were met (p=0.005); results were robust when assessed using a per-protocol analysis. 362/554 pts (65.3%) with B cell NHL received R with protocol therapy: RRs were similar between arms in pts with and without prior R exposure, and with and without R added to GDP or DHAP. The transplantation rate was 51.8% for GDP vs 49.3% for DHAP (per protocol analysis; p = 0.49); 6 pts in each arm could not mobilize adequate PBSCs. At a median follow-up of 53 months, 4 year EFS was 25.6% and 26.1% (HR 0.99, p=0.95) and 4 year OS 39.0% and 39.1% (HR 1.03, p=0.78) for GDP and DHAP, respectively. Pts receiving GDP experienced less grade 3–4 toxicity (47 vs 61%, p=0.0003), including febrile neutropenia (9 vs 23%, p<0.0001), platelet transfusion during the first 2 treatment cycles (18% vs. 32%, p < 0.0001) and AEs requiring hospitalization (18 vs 30%, p=0.0005). One pt in each arm died from infection during GDP/DHAP therapy (0.3%). Compared to baseline, superior mean and greater-than-minimally-important change scores for QoL were seen during and/or after 2 treatment cycles in the GDP group when assessed using FACT-LYM, the Trial Outcome Index for FACT-LYM and the lymphoma-specific subscale. Stratified by important baseline characteristics, in univariate analysis no variables were associated with response; in multivariate analysis, ECOG PS, stage and number of sites of disease were significantly associated with OS; age and stage were associated with EFS.

Conclusion:
The response rate to GDP is not inferior to the standard regimen DHAP prior to ASCT for aggressive lymphomas and GDP resulted in similar rates of transplantation, EFS and OS. GDP can be given in the outpatient setting with significantly less toxicity, superior QoL scores and reduced need for hospitalization. This study supports the use of GDP as a new standard in practice and in future studies focused on improving salvage therapy approaches.

Disclosures:
Crump: Roche Canada: Membership on an entity's Board of Directors or advisory committees. Off Label Use: Gemcitabine for treatment of lymphoma. Kuruvilla:Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Macdonald:Roche Canada: Membership on an entity's Board of Directors or advisory committees, Research Funding. Kukreti:Roche: Honoraria. Kouroukis:Roche: Honoraria. Meyer:Dr. Meyer has received honoraria from Lilly re role on a DSMC: Honoraria. Olney:Roche: Consultancy.